OptiBiotix Health PLC New health claims for SlimBiome in Australia
October 17 2022 - 2:00AM
RNS Non-Regulatory
TIDMOPTI
OptiBiotix Health PLC
17 October 2022
OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")
New health claims for SlimBiome(R) in Australia
OptiBiotix Health plc (AIM: OPTI), a life sciences busi ness d
eveloping compounds to tackle obesity, cardiovascular disease and
diabetes , announces additional new health claims for SlimBiome(R)
containing products in Australia. This will help to further
differentiate and advance their market share in health &
wellness, sports nutrition and weight management markets.
In accordance with the Australia New Zealand Food Standards Code
("FSANZ"), OptiBiotix has completed a systematic review of the
scientific literature for its prebiotic weight management aid
SlimBiome (R) which allows it to make four new general level health
claims on their product packaging and general advertising. These
claims are:
- SlimBiome(R) contributes to the enhancement of the feelings of
fullness and helps you stay fuller for longer
- SlimBiome(R) contributes to the enhancement of satiety,
feelings of fullness, reduced feelings of hunger, food cravings and
the desire to eat
- SlimBiome (R) supports digestive health by maintaining and/or
improving the gut microbiome, by promoting gut microbiome diversity
and a healthy intestinal bacterial balance
- SlimBiome(R) supports and improves digestive health by
promoting the growth and diversity of beneficial bacteria in the
gut
The systematic review evaluates whether there is sufficient
evidence to establish a relationship between a food or property of
food and a health effect (food-health relationship) and includes an
extensive review and ranking of data, assessment of quality of the
studies and preparation of a dossier to meet requirements of
Schedule Six of the FSANZ .
The extensive dossier built by OptiBiotix enables OptiBiotix
partners in Australia to notify FSANZ and apply these claims to
communicate the key Unique Selling Points (USPs) of their products
containing SlimBiome (R) which will help differentiate their
products from, and gain market share against, mainstream
competitors and stand out in the health & wellness, weight
management and sports nutrition categories.
SlimBiome(R) is a patented prebiotic weight management aid used
as such or in formulated products in the health & wellness,
sports nutrition and weight management categories. SlimBiome (R) is
supported by independent human clinical studies which show it
reduces hunger, cravings for sweet and savoury foods, and fat
intake. It helps people stick to the diet plan they have
undertaken. Consumers who used SlimBiome (R) in combination with a
calorie restricted diet experience a relief from feeling hungry and
have fewer cravings for food, leading to easier and more
sustainable dieting and lose on average an additional 2kg of fat
per month, improving body composition.
SlimBiome (R) has achieved multiple industry awards. The three
major awards are: European Weight Management Ingredient of the Year
(NutraIngredients 2018), Asia Weight Management Ingredient of the
Year (NutraIngredients 2019), and most recently, best weight
management product in the USA (Nutrition Industry Executive Award
2021). Depending on the market, SlimBiome (R) is also marketed
under tradenames OptiBiome (R) and LeanBiome (R) .
René Kamminga, C EO of O pti B i oti x Limited, a wholly owned
subsidiary of OptiBiotix Health plc, c o m mented: "This important
step forward enables our customers in Australia to notify FSANZ
through a simple process and make health claims that are meaningful
to their consumers that clearly differentiate their products from
mainstream competition. It demonstrates our commitment to grow with
our chosen customers and this will further accelerate the growth in
our market position in Australia both online and offline in
pharmacy and retail channels. SlimBiome (R) now carries health
claims with the European Food Safety Authority (EFSA), with Health
Canada and FSANZ, some of the most challenging regulatory
environments worldwide. It truly gives brands in health &
wellness, sports nutrition and weight management the science to
stand out in their category. I want to specifically thank our
scientific and regulatory team who put a great effort in to make
this possible."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
This communication is a "Reach" announcement. Reach is a
non-regulatory news service. By using this service an issuer is
confirming that the information contained in this announcement is
of a non-regulatory nature. Information required to be notified
under the AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUSAVRUBURAAA
(END) Dow Jones Newswires
October 17, 2022 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024